Finch Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

Finch Therapeutics is a biotechnology research company based in Somerville, Massachusetts, with 11-50 employees. The company maintains a portfolio of microbiome assets, including CP101, an orally administered candidate with Phase 2 data in recurrent CDI from a randomized, placebo-controlled trial and a Phase 2 open-label study. Finch also has pre-clinical assets targeting ulcerative colitis, Crohn's disease, and autism spectrum disorder. The company maintains an intellectual property estate with more than 70 issued U.S. and foreign patents related to donor-derived and donor-independent microbiome therapeutics. In January 2023, Finch announced the discontinuation of its Phase 3 CP101 trial in recurrent CDI and a shift to focus on its IP and other assets; in April 2023, the company partnered with Brigham and Women's Hospital to study CP101 in patients with mild-to-moderate ulcerative colitis.

Sign up for free to view info

Email Format Employee directory